

The access of GLP-1 receptor agonists to the brain Current understanding

Anna Secher, MSc, PhD

Scientific Director, Global Drug Discovery Novo Nordisk The National Academies' Forum on Neuroscience and Nervous System Disorders September 10th 2024

Washington, USA

Presenter disclosure

- Anna Secher reports the following:
 - Employee of, and shareholder in, Novo Nordisk A/S


The story of GLP-1 as a physiologically relevant satiety signal started in 1996

A role for glucagon-like peptide-1 in the central regulation of feeding

M. D. Turton, D. O'Shea, I. Gunn, S. A. Beak, C. M. B. Edwards, K. Meeran, S. J. Choi, G. M. Taylor, M. M. Heath, P. D. Lambert, J. P. H. Wilding, D. M. Smith, M. A. Ghatei, J. Herbert^{*} & S. R. Bloom[†]

Endocrine Unit, Department of Medicine, Royal Postgraduate Medical School, Hammersmith Hospital, Du Cane Road, London W12 ONN, UK * Department of Anatomy, University of Cambridge, Downing Street, Cambridge CB2 3DY, UK


NATURE · VOL 379 · 4 JANUARY 1996



Reduction of food intake in fasting rats


GLP-1 versus control; ^a*p*<0.05; ^b*p*<0.01

Broad GLP-1R expression in the brain in preclinical models



GLP-1R identified in 50+ regions

High translation to other species




Brain access is restricted


The brain is highly vascularized, but vessel walls form the **Blood-Brain-Barrier (BBB).** Molecules that pass the BBB can access most parts of the brain (parenchyma)


The **pituitary** and a few other regions of the brain (circumventricular organs, CVO's) have fenestrated capillaries and provide direct access from the circulation. Cerebro-Spinal Fluid (CSF) is secreted into the ventricular space from Choroid Plexus (CP). The CP contains a **Blood-CSF Barrier** (BCSF).

How can we measure access into the brain?



Green vessels in the brain stained by lectin






Non lipidized molecule

Lipidized molecule sticks to the membrane

GLP-1R agonists target and activate both overlapping and non-overlapping brain structures in rodents



C57/BL6, 5 days S.C dose semaglutide^{VT750}, 30-100nmol/kg



septum, hypothalamus, and hindbrain

> Secondary activation in regions associated with control of food intake and reward

Several GLP-1Rs in the brain


GLP-1R targeting in

GLP-1R, glucagon-like peptide 1 receptor Gabery S et al. JCI Insight 2020;5:e133429



c-Fos=marker for neuronal activation DIO, single I.V. dose semaglutide, 24nmol/kg

GLP-1 seems to target the same brain areas as the GLP-1 analogues




Liraglutide⁷⁵⁰

GLP-1⁷⁵⁰


Liraglutide⁷⁵⁰

GLP-1750

How do GLP-1R agonists gain access into the brain?



Tanycytes are specialized cells lining the brain ventricular systems






Csaba Fekete Institute of Experimental Medicine Hungarian Academy of Sciences

Secher A et al. J. Clin. Invest 2014;124:4473–88, Gabery S et al. JCI Insight 2020;5:e133429

Key takeaways from brain access of GLP-1R binding peptides





THANK YOU FOR YOUR ATTENTION

Anna Secher, MSc, PhD Scientific Director , Global Drug Discovery

Copenhagen, Denmark

